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of a particular device after having had extensive
clinical experience. It is therefore important that
laser surgeons examine manufacturers’ supporting
data, decipher their claims, and have a thorough
understanding of any bias at play among key opinion
leaders (physician investigator-industry relationship)
in order to deliver high-quality, patient-centered,
and cost-effective care.

Abstract
This manuscript addresses the significant
considerations concerning the development and
use of medical devices in dermatology. With the
rapidly growing demand and booming market
for medical devices, especially lasers, it is crucial
that dermatologists become familiar with the
nuances associated with supporting clinical studies,
consumer-driven marketing strategies, and the
complex relationships that exist between physicians,
industry, and consumers. An examination of these
relationships includes an overview of the potential
biases pertaining to advisory panels and treating
clinicians. The aim of this paper is to serve as an
introduction to the background of medical devices
and to offer dermatologists important information
on what should be considered before recommending
treatment.

Keywords: medical devices; lasers; dermatology;
aesthetics; physician patient relationship
Over the past several decades, there has been an
explosion of medical devices introduced to the world
of aesthetics. Although they each have intended
purposes, the research supporting their claims is of
variable quality. They are generally marketed with
an overly optimistic assurance of promise. Although
the Food and Drug Administration (FDA) plays an
important role in establishing safety, there is less of
an emphasis on efficacy. Thus, physicians are often
handed the obligation of evaluating these devices in
their clinical practices with only limited evidence of
quality science and proof of benefit. Clearly, this is not
always the case, but it is not unusual that clinicians
will elaborate on the relative benefits (or lack thereof )

The use of medical devices for specific indications
would ideally be determined with the assistance of
data from long-term, high-quality research studies.
However, device manufacturers are generally
small-cap companies without the deep pockets
to perform extended multi-center studies that are
characteristic of larger pharmaceutical corporations.
Holding them to similar standards would endanger
their tremendous ingenuity and agility. With the
FDA’s Section 510(k) route, companies can submit
information to establish that their devices are
‘substantially equivalent’ to those that are currently
marketed and subsequently receive clearance for
use [1]. As a result, the laser surgeon is often left with
some doubt as to whether or not to recommend
treatments based on this less rigorous analysis. One
such example would be the recently introduced
robotic hair transplant system, which was cleared
by the FDA through the 510(k) route. Although
revolutionary and groundbreaking compared to
former manual techniques, limited studies exist and
few clinicians possess familiarity with the device. In
situations like this, specialized experts should be
called upon to fill the gap between the literature and
clinical practice. Clinicians are encouraged to seek
guidance from those who are more experienced
before attempting to use any of the newer devices.
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Manufacturers rely heavily on consumer-driven
marketing strategies in an effort to up-sell the use
of their medical products [2]. Moreover, the media
quickly follows their marketing, which is generally
ahead of the science. In the aesthetic realm,
advertisements often provide illusions of painless,
quick cures with the promise of ageless beauty. This
can create unrealistic expectations, and in the event
that these expectations are unmet, patients may be
unsatisfied with their care. Patients may be extremely
impressed with devices (and in particular with
‘lasers’) and ignore their potential risks, perceiving
them to be technological miracles regardless of the
specific end user [3]. One such example is the use of
lasers for the treatment of onychomycosis. Although
the marketing of these devices has suggested a rapid
cure, this is quite contrary to its rather low efficacy
and lengthy timeline needed to achieve clinical
improvement. In such situations, it is important for
clinicians to correct any misconceptions, inform
patients of the available data, educate them on safety
profiles, and offer realistic expectations for what can
be achieved.
It is also important for us all to realize that bias is
inherent. In this regard, there are three types of
clinicians: 1) Those who are intimately associated with
the development of a device, who are likely to be the
best informed but also the most biased, 2) Those who
are not involved in the development but possess a
good understanding, who are less informed but also
less biased, and 3) Those who are non-specialists
lacking any familiarity, who are the least informed
but also the least biased. Which category a clinician
falls into may influence opinions and treatment
recommendations. It is important that we include all
three categories in our decision making.

practices. Although no solid data exists to determine
its full effects, it was recently shown that plastic
surgery exhibited the lowest prevalence (54.5%)
of industry financial relationships following the
enactment of the Sunshine Act when compared to
other surgical subspecialties (57.9-87.8%, [5]). Though
this may give comfort to some, others might lament
the restrictions placed on our more scientificallyinclined specialists as they are discouraged from
performing much-needed clinical studies for fear of
being labeled as mischievous by the public.
In this burgeoning market, dermatologists and plastic
surgeons largely serve as gatekeepers between the
medical device industry and consumers. Clinicians
have professional, moral, and ethical obligations
to deliver efficient, safe, and cost-effective care to
patients. They deserve nothing less than a thorough
analysis of any new device that comes to market.
Those who are considered key opinion leaders
and those who have investigated these devices
must not deviate from objectivity when reporting
the outcomes at our national meetings and in our
specialty journals. An association with industry is
to be encouraged, applauded, and appreciated,
especially when the outcomes are modest and
reported as such.
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to the public [4]. Hailed as a groundbreaking
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and empower patients. It has been speculated that
overall physician payments have declined owing to
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